The Infectious Disease Research Group integrates professionals in medicine, nursing, and different biomedical specialties, which perform basic and clinical research. The research lines of the group are focused on the study of antimicrobial resistance, infections related to health care and complex community infections, infections in immunocompromised patients, human immunodeficiency virus infection, sexually transmitted diseases, and international health (health problems that cross geographical borders with special emphasis on tropical diseases). The different research lines are complemented by clinical research activities and others carried out in biological experimentation laboratories. We collaborate with national and international groups and coordinate two clinical research networks at the Center for Biomedical Research Network on Infectious Diseases (CIBERINFEC).
Group Leader
Israel Molina Romero, María José Buzón Gómez
Principal Investigator (PI)
Meritxell Genescà, Vicenç Falcó, Òscar Len, Joaquín Burgos, Joan Gavaldà, Jordi Navarro, Fernando Salvador, Adrián Sánchez, Núria Serre, Inés Oliveira, Marisa Aznar, Jordi Gómez,
Researchers
Dolors Rodríguez, Núria Fernández, Adrià Curran, Isabel Ruiz, Ibai Los Arcos, Adaia Albasanz, Maider Arando, Diana Pou, Begoña Treviño, Raisa Morales, José Santos, Daniel Pieren, Yasmine Baktash, Carme Ferrer, Montse LLinàs
PhD Students
Pau Bosch, Paula Suanzes, Juan Espinosa, Ester Márquez, Júlia Sellarés, Arnau Monforte, Joan Martínez, Jorge García, Vicente Descalzo, Patricia Álvarez, Miguel Villamarin, Blanca Marzo, Anna Falcó, Cristina Kirkegard, Nerea Sánchez, David Perea, Ana Gallego, Cristina Mancebo, Estela Muñoz, Marta Palau
Lab Technicians
Joan Rey, Xavier Gomis
Nursing and Technical Staff
Esperanza Esteban, Marta Sanchiz, Lucía Rodríguez, Paola Vidovic, Bibiana Planas, Elisabet Ferrer, Claudia Broto, Desideria Martínez, Silvina Magnani, Rosa Badía, Nuria Saborit
101
PUBLICATIONS
63.4%
%Q1
1,119
IMPACT FACTOR
11.08
AVERAGE IMPACT FACTOR
SELECTED ARTICLES
Monforte A, Los-Arcos I, Martín-Gómez MT, Campany-Herrero D, Sacanell J, Berastegui C, Márquez-Algaba E, Sempere A, Nuvials X, Deu M, Castells L, Moreso F, Bravo C, Gavaldà J, Len O
Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study)
Microbiol Spectr. 2022 Feb 23;10(1):e0178421
DOI: doi: 10.1128/spectrum.01784-21.
IF: 9.043
Sempere A, Viñado B, Los-Arcos I, Campany D, Larrosa N, Fernández-Hidalgo N, Rodríguez-Pardo D, González-López JJ, Nuvials X, Almirante B, Escolà-Vergé L
Ceftazidime-Avibactam plus Aztreonam for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria
Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0075122
DOI: doi: 10.1128/aac.00751-22
IF: 5.938
Antonio Astorga-Gamaza, Judith Grau-Expósito, Joaquín Burgos, Jordi Navarro, Adrià Curran 1, Bibiana Planas, Paula Suanzes, Vicenç Falcó, Meritxell Genescà and Maria J Buzon
Identification of HIV-reservoir cells with reduced susceptibility to antibody-dependent immune response
eLife 2022. PMID: 35616530 PMCID: PMC9177146
DOI: doi: 10.7554/eLife.78294
IF: 8.713
Bosch-Nicolau P, Salvador F, Sánchez-Montalvá A, Franco-Jarava C, Arrese-Muñoz I, Sulleiro E, Roure S, Valerio L, Oliveira-Souto I, Serre-Delcor N, Pou D, Treviño B, Aznar ML, Espinosa-Pereiro J, Molina I
Association of HLA-B∗35 and moderate or severe cutaneous reactions secondary to benznidazole treatment in chronic chagas disease
Clin Microbiol Infect. 2022 Jun;28(6):881.e1-881.e5
DOI: doi: 10.1016/j.cmi.2021.11.021
IF: 13.31
Márquez-Algaba E, Iacoboni G, Pernas B, Esperalba J, Los Arcos I, Navarro V, Monforte A, Beas F, Albasanz-Puig A, Carpio C, Barba P, Ruiz-Camps I
Impact of Cytomegalovirus Replication in Patients with Aggressive B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy
Transplant Cell Ther. 2022 Dec;28(12):851.e1-851.e8
DOI: doi: 10.1016/j.jtct.2022.09.007
IF: 5.609
Determinación de biomarcadores pronósticos de disfunción crónica del injerto tras infección vírica del tracto respiratorio inferior en receptores de trasplante pulmonar (Referencia: PI20/01080)
Principal Investigator: Oscar Len Abad
Agency: Fundación Invest. Médica Mutua Madrileña
Funding: 80,000 €
Period: 01/01/2021 - 31/12/2023
The efficacy of Lauric Acid, a dietary fatty acid, at impacting the HIV latent reservoir. The FATHIV clinical study (Referencia: PI20/01080)
Principal Investigator: IP:Joaquin Burgos Cibrian. Collaborators: Adria Curran Fàbregas, Bibiana Planas Ribas, Paula Suanzes Diez
Agency: Instituto de Salud Carlos III
Funding: 135,520 €
Period: 01/01/2021 - 31/12/2023
Controlled Open Randomized Clinical Trial to assess efficacy and safety of an anti-TB drug combination based on high dose Rifampicin, high dose Moxifloxacin and Linezolid for DS smear positive pulmonary TB during the first 8weeks of treatmen (Referencia: PI20/01378)
Principal Investigator: IP: Adrián Sánchez Montalvá. Collaborators: Maria Luisa Aznar Ruiz de Alegria, Mª Teresa Tórtola Fernández
Agency: Instituto de Salud Carlos III
Funding: 187,550 €
Period: 01/01/2021 - 31/12/2023
AcToVax4NAM – Increased Access To Vaccination for Newly Arrived Migrants (Referencia: ACTOVAX4NAM_CHAFEA/HP-PJ-2020)
Principal Investigator: IP: Nuria Serre Delcor. Collaborators: Styliani Evangelidou
Agency: EUROPEAN COMMISSION
Funding: 94,759.20€
Period: 01/05/2021 - 30/04/2024
Validación del Anticuerpo Biespecífico Ab-Bi16/32 dirigido a los reservorios virales del VIH (Bi-Cure) (Referencia: PID2021-123321OB-I00)
Principal Investigator: Maria J. Buzon
Agency: Agencia Estatal de Investigación. Proyectos Generación de Conocimiento
Funding: 365,000 €
Period: 01/09/2022 - 31/08/2025
BIOFILM PREVENTING SYSTEM FOR RESPIRATORY MEDICAL DEVICES
Priority Number: EP 2021/074309
Priority Date: 06/07/2021
Applicants: 100% VHIR
SYSTEM FOR THERMOTHERAPY TREATMENT OR PREVENTION OF ANTIMICROBIAL RESISTANT OR BIOFILM INFECTIONS
Priority Number: IB 2017/000186
Priority Date: 01/03/2016
Applicants: VHIR: 47,5% / IBEC: 30% / ICREA: 15% / ICN2: 7,5%
BI-FUNCTIONALIZED NANOPARTICLES, PROCESS FOR ITS PREPARATION AND USES THEREOF
Priority Number: EP 2020/071635
Priority Date: 31/07/2020
Applicants: 66,25% VHIR 22,50% ICREA 11,25% ICN2
ENTRECTINIB AS ANTIVIRAL AGENT FOR THE TREATMENT OF CORONAVIRUS INFECTIONS
Priority Number: EP 2022/070594 22.07.2022
Priority Date: 23/07/2021
Applicants: IMIM 80 % VHIR 20%
eCOREs
